Tag: subspecialty reads

Breast Imaging 2025–26: Risk Models, CEM/MRI Momentum — RSNA Preview

RSNA 2025 is putting real energy behind risk-adjusted screening and the evolving roles of contrast-enhanced mammography (CEM) and breast MRI. For breast programs, the takeaway is practical: risk tools are moving from the research poster to the reading room, and CEM/MRI decisions are becoming operational levers you can plan around—especially for dense-breast pathways and overflow routing to subspecialists.

What’s new at RSNA: risk from the image itself

RSNA’s breast-imaging preview highlights sessions on image-only, 5-year breast cancer risk models, external validation work, and how MRI adds value in multi-modal AI. It also calls out global screening updates and a deeper look at background parenchymal enhancement (BPE) on MRI. RSNA

In parallel, the FDA granted De Novo authorization to the first image-only AI risk platform that predicts 5-year risk directly from a screening mammogram—an inflection point that makes risk-adjusted pathways far more scalable. Coverage from Radiology Business and BCRF explains the authorization and clinical intent. Radiology Business

Why it matters: average-risk guidance in the U.S. now begins screening at age 40 (USPSTF, 2024). Programs can layer image-based risk on top of that baseline to triage who needs annual vs. short-interval follow-up and who merits supplemental imaging. USPSTF

CEM is earning a seat next to MRI

Expect exhibits and sessions positioning CEM as a cost-effective, accessible adjunct—particularly for dense-breast populations and diagnostic workups. RSNA News recently framed CEM as a practical alternative to MRI in some screening/diagnostic scenarios, and new peer-review literature is refining technique (e.g., lower volume/higher-iodine contrast while preserving diagnostic performance). RSNA

On outcomes, the RACER trial in The Lancet Regional Health – Europe reported that using CEM as primary imaging for recalled women improved the accuracy and efficiency of the work-up compared with conventional imaging—evidence that will influence protocols beyond the show floor. The Lancet

MRI still leads for sensitivity—BPE is your underused signal

Breast MRI remains the sensitivity champion for high-risk patients and for problem solving. This year’s RSNA content spotlights BPE—how the level of background enhancement relates to tumor biology and outcomes. Recent reviews (2024–2025) synthesize BPE’s predictive/prognostic value, including associations with pathologic complete response after neoadjuvant therapy and survival in certain subtypes. SpringerLink

Practical move: standardize how you document BPE and incorporate it into structured reports and risk conferences; it’s becoming more than a descriptive footnote.

What to ask vendors at RSNA

  1. Risk engine proof: “Show external validation and calibration plots by density and race; how does your image-only model integrate into our mammography worklist and letters?”
  2. CEM logistics: “Demonstrate CEM acquisition workflows, contrast protocols, and how your viewer handles subtraction/kinetics alongside priors.”
  3. MRI + BPE analytics: “Can we standardize BPE capture in structured reports and trend it across treatment?”

As risk-first screening, CEM, and MRI gain real traction, the winners will be the programs that operationalize them quickly and consistently. If you’re planning your 2026 breast-imaging playbook, stop by Vesta at RSNA to see how our subspecialists, standardized templates, and overflow routing make risk-adjusted pathways usable on day one.

Imaging the Individual — In the Trenches: AI, Personalization & Equity at RSNA 2025

RSNA’s 2025 theme, Imaging the Individual, isn’t just about futuristic science—it’s about doing the basics better for each patient, every day. The official Trending Topics preview highlights three threads cutting across subspecialties: AI you can deploy, personalized care you can operationalize, and equity you can measure. This guide translates those themes into practical checkpoints hospitals and imaging centers can use right now. RSNA

1) AI that graduates from pilot to practice

This year’s agenda emphasizes real outcomes over proofs of concept: reader-in-the-loop tools, bias monitoring, and governance. In breast imaging alone, RSNA previews spotlight external validation for image-only risk models and integration of MRI signals into multimodal AI—clear signals that “personalization” is landing in routine workflows. Bring vendor questions that force specifics: external validation cohorts, drift detection, and how metrics (TAT, recalls, rework) appear in your dashboard. RSNA

What to set up before RSNA: define 3–5 outcome metrics and insist every demo shows pre/post performance tied to those measures. Use QIBA concepts to push for standardized inputs/outputs so results are reproducible across scanners and sites. QIBA Wiki

2) Personalization that reaches the reading room

Personalization isn’t only radiogenomics. RSNA’s preview points to risk-stratified pathways you can actually run: e.g., image-only 5-year breast cancer risk at the point of screening to route patients into annual vs. short-interval follow-up or supplemental imaging (CEM/MRI). That pairs well with updated U.S. recommendations: screening beginning at age 40 for average-risk women, then adjusting based on risk and local policy. Build routing rules, templates, and letters now, so RSNA demos can plug into your plan.

Operational checklist:

  • Map risk thresholds → next steps (annual vs. short-interval, CEM/MRI).
  • Standardize templates so risk outputs appear consistently in reports and patient letters.
  • Decide who reviews outlier risk flags and how quickly (SLA).

3) Equity you can instrument—not just endorse

RSNA is foregrounding health equity, with sessions on encoding equity in AI and addressing access gaps for underserved communities. Equity becomes real when you can see it in your data: turnaround times by language, missed-appointment patterns by zip code, recall rates by screening site, and AI performance by subgroup. Build those slices into your analytics now; then ask vendors to show subgroup performance in their dashboards.

Practical moves:

  • Add demographic and language filters to your TAT and recall reports.
  • Require AI vendors to show calibration and error analysis by subgroup.
  • Stand up multilingual patient letter templates to support new screening starts at 40. USPSTF

4) CEM/MRI momentum: choose the lever that fits your service line

RSNA coverage calls out CEM as an increasingly practical adjunct—especially useful for dense-breast populations and diagnostic workups where capacity or cost limits MRI. The RACER trial reported higher accuracy and efficiency for CEM as the primary exam for recalled women vs. conventional imaging—evidence that can justify protocol changes and equipment planning. Meanwhile, MRI retains the sensitivity crown, with renewed attention on background parenchymal enhancement (BPE) as a signal worth documenting consistently.

 

Action items:

  • Decide where CEM fits: diagnostic recall pathway, dense-breast supplemental strategy, or both.
  • Add BPE level to structured MRI reports and trend it during therapy response clinics.

5) Governance, not guesswork

If personalization is the “what,” governance is the “how.” Use QIBA ideas—claim definitions, acquisition standards, and profile adherence—to control variability across devices and shifts. Tie RSNA learnings to a written governance plan with three parts: 1) protocol book (who owns it, update cadence), 2) quality book (metrics, subgroup views), and 3) AI book (approval process, monitoring, rollback).

6) Where teleradiology extends your capacity

Personalization increases complexity at peaks (recalls, dense-breast seasons, MR backlogs). A teleradiology partner helps you keep individualized pathways moving: standardized templates, subspecialty over-reads, and after-hours coverage that adheres to your risk rules and equity metrics—so “Imaging the Individual” doesn’t stop at 5 p.m.

Headed to RSNA?

 

Visit Vesta at Booth 1346 (South Hall) to see how we make “Imaging the Individual” work in real clinics—then enter to win a 1-year Medality CME subscription. Don’t wait: email “RSNA CME Entry” to info@vestarad.com now for a reserved entry, and show your confirmation at the booth for a bonus entry.

Vesta Teleradiology Heads to RSNA 2025: AI + Expertise = Faster, Smarter Imaging Coverage

 

Every year, the Radiological Society of North America (RSNA) brings together innovators shaping the future of medical imaging. This November 30–December 3, 2025, the Vesta Teleradiology team is proud to join that community at RSNA 2025 in Chicago — showcasing how AI and human expertise combine to deliver faster, smarter imaging coverage for hospitals and imaging centers nationwide.

Meet Vesta at Booth 1346 — South Hall

At Booth 1346, attendees can discover how Vesta helps healthcare facilities overcome some of today’s biggest radiology challenges — from staffing shortages to increasing imaging volumes — without compromising patient care.

Vesta’s solutions are designed to help your organization:

  • ✅ Gain 24/7 radiology coverage without the burnout
  • ✅ Access fellowship-trained subspecialists across all modalities
  • ✅ Deliver faster turnaround times with AI-assisted workflow tools
  • ✅ Scale imaging services without adding staff
  • ✅ Rely on dependable IT services and seamless PACS integration

How Vesta Combines AI + Human Expertise

Teleradiology isn’t just about remote reads — it’s about precision, speed, and collaboration. Vesta’s radiologists use advanced AI-assisted workflow technology to prioritize cases, enhance diagnostic consistency, and streamline communication with hospitals and imaging centers.

AI tools don’t replace radiologists; they empower them. By automating repetitive tasks and highlighting critical findings faster, AI allows Vesta’s board-certified radiologists to focus where their expertise matters most — delivering accurate interpretations and improving patient outcomes around the clock.

Dependable Excellence, Every Time

Since its founding, Vesta has remained committed to providing dependable, high-quality radiology coverage that healthcare organizations can trust. Whether you need overnight support, overflow assistance, or full departmental coverage, Vesta’s network of U.S.-based, fellowship-trained subspecialists ensures that every scan gets the attention it deserves — anytime, anywhere.

Join Us in Chicago

If you’re attending RSNA 2025, we’d love to meet you in person. Stop by Booth 1346 in the South Hall to see how Vesta’s combination of human insight and artificial intelligence is helping healthcare facilities achieve diagnostic excellence — without adding to their workload.

RSNA 2025 — Chicago, IL
 November 30 – December 3, 2025
 VESTARAD.COM

Vizamyl’s New PET Label: Quantify & Monitor Amyloid—What It Means for Imaging Teams

 

What changed—and why it matters

The FDA has expanded the label for flutemetamol F 18 (Vizamyl), enabling quantification of amyloid plaque burden and long-term therapy monitoring in Alzheimer’s disease. This shift moves amyloid PET beyond a qualitative “positive/negative” decision toward objective, longitudinal assessment that can inform treatment choice, dose intervals, and discontinuation decisions. Business Wire

Professional groups report the update aligns amyloid PET with the clinical era of disease-modifying anti-amyloid therapies (e.g., lecanemab, donanemab), clarifying roles for baseline confirmation, on-treatment monitoring, and response tracking in routine care. Notably, SNMMI stated the FDA granted supplemental indications—including quantitative measurement and use for therapy monitoring—to three amyloid PET agents (flutemetamol F-18/Vizamyl, florbetapir F-18, and florbetaben F-18). SNMMI

Operational updates for radiology leaders

  • Protocols & quant pipelines: Build or validate a quant workflow (SUVr or comparable metrics) that’s scanner-calibrated and reproducible across sites. If you operate multi-vendor fleets, document harmonization steps in your SOPs.
  • Structured reports: Add fields for quantified burden at baseline, change from baseline, and interpretive guidance tied to therapeutic decisions (initiation, continuation, or discontinuation).
  • Scheduling & throughput: Expect rising referral volume from neurology and geriatrics as therapy monitoring enters routine practice; protect access with extended hours or overflow capacity.
  • Quality & governance: Define thresholds for biologically meaningful change, reader training for quant review, and reconciliation rules when quant and visual impressions diverge.

For additional context, trade coverage underscores that the updated label formally removes previous limitations around therapy monitoring and permits quant analysis in routine reporting. Empr

How Vesta Teleradiology helps

Vesta’s subspecialty neuro and nuclear medicine radiologists provide:

  • Amyloid PET expertise: Visual+quant reads with structured templates aligned to your therapy pathway.
  • Coverage when you need it: After-hours, weekends, or daytime overflow—without sacrificing turnaround time.
  • Interoperability: Seamless delivery to your PACS/RIS and EMR; clear flags for therapy decisions and recall intervals.
  • QA you can see: Peer review, consistency checks across readers, and optional double-reads during program ramp-up.

If you’re standing up or scaling amyloid PET services, we can supply immediate subspecialty coverage and templates tuned to your neurologists’ needs.

 

Supporting Women’s Health with Subspecialty Teleradiology: National Women’s Health Week 2025

Each May, National Women’s Health Week serves as a reminder of the importance of preventive care, early detection, and access to high-quality medical services for women across the country. Among these essential services, breast imaging stands out as a cornerstone of women’s health — and timely, accurate interpretation of mammograms plays a vital role in early detection of breast cancer.

But what happens when a facility doesn’t have immediate access to a subspecialty-trained breast radiologist?

That’s where teleradiology steps in.

At Vesta Teleradiology, we support women’s health initiatives year-round by providing reliable, fast, and compliant mammography interpretations, especially for facilities that may not have in-house specialists available.

The Need for Expert Mammography Interpretation

According to the CDC, breast cancer is the second most common cancer among women in the U.S., and regular mammograms are the best way to detect breast cancer early, when it’s easier to treat and before symptoms appear1. The American College of Radiology (ACR) also notes that interpretation by radiologists trained in breast imaging can improve detection rates and reduce false positives2.

However, many imaging centers and rural hospitals don’t have a dedicated breast radiologist on-site — and delays in interpretation can lead to gaps in care or unnecessary anxiety for patients.

Female patient undergoing a mammogram with a radiologic technologist in a medical exam roomThis challenge is magnified by a growing shortage of radiologists, particularly those specializing in breast imaging. A 2023 workforce survey from the Association of American Medical Colleges (AAMC) highlighted that more than 50% of practicing radiologists are over the age of 55, and retirements are outpacing new entrants. Breast imaging — already a subspecialty with fewer practitioners — is feeling the strain. Many facilities are facing longer turnaround times or are unable to offer advanced imaging interpretation consistently.

In addition, burnout remains a real concern. Breast radiologists face high volumes and frequent callbacks, which can affect accuracy and job satisfaction. Teleradiology can help balance the workload by offering overflow and relief coverage, supporting both the health system and the radiologists themselves.

How Teleradiology Closes the Gap

Vesta Teleradiology provides healthcare facilities with remote access to subspecialty-trained radiologists, including experts in breast imaging. This allows imaging centers, OB/GYN clinics, and hospitals to meet women’s health needs without overextending in-house teams.

Here’s how we help:

  • Full MQSA-compliant interpretations
  • Support for both screening and diagnostic mammograms
  • 24/7/365 availability, including STAT and overflow reads
  • Subspecialty reads in breast MRI, ultrasound, and 3D mammography (tomosynthesis)
  • Seamless PACS integration and secure data exchange

Whether your site needs full-time coverage or help during vacation season, we ensure that your patients receive timely, high-quality reads.

National Women’s Health Week Is the Perfect Time to Prioritize Imaging Readiness

National Women’s Health Week 2025 runs from May 12–18 and encourages women to schedule important preventive screenings — including mammograms.

Facilities should be prepared for increased volume during this time and throughout Breast Cancer Awareness campaigns later in the year (October). Having a trusted teleradiology partner means you can handle increased demand without sacrificing quality or turnaround times.

Vesta Teleradiology: Your Partner in Women’s Imaging

At Vesta, we believe in supporting facilities that support women. Our flexible coverage options and experienced radiologists help ensure that women’s health screenings — including mammograms — are interpreted accurately, securely, and quickly.

Whether you’re preparing for Women’s Health Week or looking for year-round coverage, we’re here to help you deliver the care your patients deserve.

Let’s improve access, together. Contact us to learn more about how Vesta can support your women’s imaging services.